Nalaganje...
Clinical Use of DPP-4 Inhibitors
DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006. They stimulate insulin secretion and inhibit glucagon secretion by elevating endogenous GLP-1 concentrations without an intrinsic hypoglycaemia risk. Their efficacy potential to lower HbA1c is in the range between 0.5 and...
Shranjeno v:
| izdano v: | Front Endocrinol (Lausanne) |
|---|---|
| Glavni avtor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Frontiers Media S.A.
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6593043/ https://ncbi.nlm.nih.gov/pubmed/31275246 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2019.00389 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|